Nutritional supplement suitable for people with six highs as well as tablets and preparation method of nutritional supplement

Abstract

The invention provides a nutritional supplement suitable for people with six highs as well as tablets and a preparation method of the nutritional supplement, and belongs to the field of food processing. On one hand, the invention provides a nutritional supplement suitable for people with six highs, and the nutritional supplement comprises the following raw materials: chlorella pyrenoidosa powder, euglena powder, xylooligosaccharide, earthworm protein, natto powder and tea theanine; on the second aspect, the invention further provides a tablet preparation method of the nutritional supplement suitable for people with six highs; the invention further provides application of the nutritional supplement or tablets of the nutritional supplement in preparation of food or health food suitable for people with six highs. Compared with the prior art, the nutritional supplement suitable for the six-high crowd has the advantage that the health indexes are obviously improved in the aspect of improving the health indexes.

Description

Technical Field

[0001] The present invention relates to the technical field of nutritional supplements, and in particular to a nutritional supplement suitable for people with six highs, a tablet thereof, and a preparation method thereof. Background Art

[0002] The "six highs" group refers to the elderly population with high blood lipids, high weight, high blood pressure, high blood sugar and high uric acid.

[0003] Hyperlipidemia refers to high cholesterol or triglycerides or low high-density lipoprotein cholesterol in the blood, which is called dyslipidemia in modern medicine. It is the main factor leading to atherosclerosis and a risk factor for the development of cardiovascular and cerebrovascular diseases. It is insidious and most of the time there are no clinical symptoms, so it is called the "invisible killer."

[0004] There is no unified method for the diagnosis of hyperlipidemia internationally or domestically. In the past, it was believed that a plasma total cholesterol concentration >5.17mmol / L (200mg / dl) could be defined as hypercholesterolemia, and a plasma triglyceride concentration >2.3mmol / L (200mg / dl) was defined as hypertriglyceridemia. Due to factors such as the different populations tested and the differences in the test methods used, the diagnostic criteria for hyperlipidemia are different in different places. However, in order to prevent and treat atherosclerosis and coronary heart disease, the appropriate plasma cholesterol level should be determined based on the patient's future risk of cardiovascular and cerebrovascular diseases. The higher the risk, the lower the appropriate plasma cholesterol level should be.

[0005] The new standard recommends starting drug treatment when the LDL-C concentration is >130mg / dl, with the LDL-C concentration <100mg / dl as the treatment target. If the risk of cardiovascular and cerebrovascular diseases in the future is very high, drug treatment should be started earlier and more stringent treatment targets should be adopted. Low HDL-C concentration is a risk factor for coronary heart disease, which is <40mg / dl. Hyperlipidemia can be divided into primary and secondary types. Primary is related to congenital and genetic factors, and is caused by single gene defects or multiple gene defects, which cause abnormal receptors, enzymes or apolipoproteins involved in lipoprotein transport and metabolism, or due to environmental factors (diet, nutrition, drugs) and unknown mechanisms. Secondary hyperlipidemia often occurs in metabolic disorders (diabetes, hypertension, myxedema, hypothyroidism, obesity, liver and kidney diseases, hyperadrenocortical function), or is related to other factors such as age, gender, season, drinking, smoking, diet, physical activity, mental stress, emotional activity, etc.

[0006] High weight means obesity. Generally speaking, high weight (obesity) itself is not fatal, but the complications brought by obesity, such as diabetes, coronary heart disease, and high blood pressure, will actually reduce life expectancy. We are against blind weight loss, and we do not advocate "keeping fat", but should try our best to keep fat and thin in moderation. In other words, you should calculate your ideal weight according to your specific situation, and then control your weight within the ideal range through diet, exercise and other measures to ensure a healthy body and a truly healthy and long life. The main purpose of controlling high weight (obesity) for flight personnel is to prevent and treat high blood lipids, high blood pressure, high blood sugar, and high uric acid; it is to prevent incapacitation in the air and ensure flight safety.

[0007] What harm does high body weight (obesity) bring? 1. It causes abnormal blood lipids. Obese people, especially those with abdominal obesity, are more likely to show hypercholesterolemia, hypertriglyceridemia, abnormally elevated low-density lipoprotein and very low-density lipoprotein than ordinary people, while high-density lipoprotein decreases. The reason why obese people are prone to hyperlipidemia is not very clear at present. The possible reasons are as follows: First, they eat a lot of fat. A diet high in saturated fatty acids can increase the level of low-density lipoprotein cholesterol; second, they store a lot of fat in the body; third, hyperinsulinemia can increase blood lipids; fourth, there are problems with the removal of blood lipids. 2. Increase cerebrovascular disease. Obese people are prone to hypertension, dyslipidemia and diabetes, and obese people with hypertension, dyslipidemia and diabetes are more likely to have problems with their brains. First of all, such people are prone to cerebral atherosclerosis. Their brain blood vessels are hard and brittle, and they are prone to rupture under the action of high blood pressure, causing dangerous cerebral hemorrhage and even life-threatening. Secondly, the level of tissue fibrinolysis inhibitor in the blood of obese people is also higher than that of ordinary people. This factor makes it difficult to dissolve blood clots once they are formed, so obese people are prone to cerebral thrombosis, that is, cerebral infarction. 3. Increase the probability of high blood pressure. Obesity is closely related to high blood pressure. Among obese people aged 40-50, the incidence of high blood pressure is 50% higher than that of non-obese people. A moderately obese person has more than 5 times the chance of high blood pressure than a person of normal weight and more than 2 times that of a mildly obese person. It is because when the human body has too much fat, sodium will be retained in the body. When the body retains sodium, the blood volume increases and the blood pressure rises at the same time. High blood pressure increases the workload of the heart and causes harm to the heart, such as hypertensive heart disease. 4. Increase the load on the heart. Some people have found that the incidence of angina pectoris and sudden death in obese people has increased by 4 times. This shows that obesity will definitely increase the burden on the heart and cause heart damage. The heart of a normal human body is like a water pump, constantly contracting and relaxing to maintain the circulation of blood. Because obese people store too much fat in their blood, the total amount of blood increases accordingly, and the heart will increase its contraction force accordingly. When the heart is overwhelmed, it can no longer effectively pump blood, causing blood to accumulate in the cardiovascular system. In severe cases, obvious heart failure may even occur. 5. Lead to fatty liver. About half of obese people suffer from fatty liver. The liver is the place where triglycerides are synthesized, but there is not much extra space in the liver to store it. The balance between triglyceride synthesis and transport in obese people is out of balance. Obese people consume more fatty acids, so the liver synthesizes more triglycerides. A large amount of triglycerides accumulate in the liver. As a result, fatty liver is formed. 6. Increase the risk of diabetes. Obesity is one of the important risk factors for diabetes. Among patients with type 2 diabetes, 80% are obese. Moreover, the longer the obesity lasts, the greater the chance of diabetes. 7. Cause bone and joint diseases. There are three main types of bone and joint diseases that may be caused by obesity: osteoarthritis, diabetic osteoarthritis, and gouty osteoarthritis.Among them, osteoarthritis is the most common and harmful. Osteoarthritis caused by obesity mainly affects the knee joints, followed by the hip joints and finger joints. Extra weight increases the pressure on the joints and aggravates the wear and tear when protecting the cartilage. 8. Obese people are prone to cancer. According to the results of epidemiological surveys, obese women are more likely to develop endometrial cancer and postmenopausal breast cancer, and obese men are more likely to develop prostate cancer; and as long as they are obese, both men and women are more likely to develop colon cancer and rectal cancer. The more severe the obesity, the higher the incidence of the above cancers. 9. Sleep apnea syndrome. The fatter a person is, the more severe the symptoms will be. 10. Gallstones. Gallstones are very common in overweight people. 11. Physical discomfort. Fat accumulation squeezes the space that should be occupied by organs. Overweight people will have difficulty breathing, walking or sitting.

[0008] Hypertension refers to a clinical syndrome characterized by an increase in systemic arterial blood pressure (systolic and / or diastolic blood pressure). Because it occurs unconsciously, it is called a "silent killer". It may be accompanied by functional or organic damage to organs such as the heart, brain, and kidneys. Hypertension is the most common chronic disease and the most important risk factor for cardiovascular and cerebrovascular diseases. The blood pressure of a normal person fluctuates within a certain range with changes in the internal and external environment. In the overall population, blood pressure levels gradually increase with age, with systolic blood pressure being more obvious, but diastolic blood pressure after the age of 50 shows a downward trend, and pulse pressure also increases accordingly. In recent years, people's understanding of the role of multiple risk factors for cardiovascular disease and the protection of target organs such as the heart, brain, and kidneys has continued to deepen, and the diagnostic criteria for hypertension have also been continuously adjusted. It is believed that patients with the same blood pressure level have different risks of cardiovascular disease. Therefore, the concept of blood pressure stratification has been developed, that is, patients with different risks of cardiovascular disease should have different appropriate blood pressure levels. Blood pressure values ​​and risk factor assessment are the main basis for diagnosing and formulating hypertension treatment plans. The goals of hypertension management are different for different patients. When facing patients, doctors judge the most appropriate blood pressure range for the patient based on the reference standards and their specific circumstances, and adopt targeted treatment measures.

[0011] Hyperglycemia is when the glucose content in the body's blood is higher than normal. It is an independent pathological change in the body. The lesion site is in the blood, and the nature of the lesion is a disorder of blood sugar metabolism. When the blood sugar value is higher than the normal range, it is called hyperglycemia. The normal value of fasting blood sugar is below 6.1mmol / L, and the normal value of blood sugar two hours after a meal is below 7.8mmol / L. If it is higher than this range, it is called hyperglycemia.

[0012] Under normal circumstances, the human body can ensure the balance between the source and destination of blood sugar through hormone regulation and neural regulation, so that blood sugar is maintained at a certain level. However, under the combined effects of genetic factors (such as a family history of diabetes) and environmental factors (such as an unreasonable diet, obesity, etc.), the two major regulatory functions are disrupted, and blood sugar levels will rise. The clinical manifestations of hyperglycemia can have obvious symptoms, such as dry mouth, frequent drinking, frequent urination, and weight loss; or they can be latent symptoms without obvious subjective discomfort.

[0013] Increased blood sugar and increased urine sugar can trigger osmotic diuresis, which can cause symptoms of polyuria; increased blood sugar and large amounts of water loss will increase blood osmotic pressure accordingly, and high blood osmotic pressure can stimulate the thirst center of the hypothalamus, causing symptoms of thirst and polydipsia; due to relative or absolute lack of insulin, glucose in the body cannot be utilized, and protein and fat consumption increase, causing fatigue and weight loss; in order to compensate for the lost sugar and maintain body activity, more food is needed; this forms the typical "three more and one less" symptom. The symptoms of polydipsia and polyuria in diabetic patients are proportional to the severity of the disease. In addition, it is worth noting that the more the patient eats, the higher the blood sugar, the more sugar is lost in the urine, and the more hungry he is, which eventually leads to a vicious cycle.

[0014] "Three more and one less" is the most common clinical manifestation of diabetes, namely polydipsia, polyphagia, polyuria and weight loss. However, at present, some diabetic patients in clinical practice have delayed diagnosis because they do not have typical "three more and one less" symptoms. Some patients with type 2 diabetes do not have obvious "three more and one less" symptoms. On the one hand, many diabetic patients are found through physical examinations that their blood sugar is only slightly elevated, and has not exceeded or only slightly exceeded the renal glucose threshold. The renal sugar excretion is very small, which is not enough to cause obvious "three more and one less" symptoms. On the other hand, it is caused by the increase in the renal glucose threshold of some patients. Under normal circumstances, all glucose is reabsorbed in the kidneys, and no sugar is excreted in the urine; if blood sugar rises slightly, the renal tubular reabsorption value will increase accordingly; but when blood sugar rises to a certain level, exceeding the maximum reabsorption range of the renal tubules, some glucose will be excreted from the urine, thus forming diabetes. This critical blood sugar value is the renal glucose threshold, and the normal value is 8.8-9.9mmol / L. Kidney disease and some other urinary system diseases will have different degrees of impact on it, and the renal glucose threshold of most elderly patients will also increase accordingly. After the renal glucose threshold increases, patients will not have diabetes even if their blood sugar is very high. Without diabetes, osmotic diuresis will not be triggered, so there will be no polyuria symptoms; without losing a lot of water, the plasma osmotic pressure will change less, and the stimulation to the hypothalamic center will be reduced accordingly, so there will be no thirst and polydipsia symptoms; without diabetes, a large amount of sugar will not be lost, so there will be no obvious hunger, and the symptoms of polyphagia will be reduced; without diabetes, the body's nutrient loss will be reduced, so the degree of weight loss can be reduced accordingly. As a result, these diabetic patients can eventually avoid the symptoms of "three more and one less".

[0015] Hyperuricemia is a metabolic disease caused by a metabolic disorder of a substance called purine in the human body, which leads to an increase of uric acid in the blood.

[0016] Clinically, normal uric acid levels are 149-416 μmol / L for men and 89-357 μmol / L for women. However, it is far from enough to control uric acid at normal levels for both gout patients and kidney disease patients with high uric acid levels. If you want to avoid large amounts of uric acid deposited in joints and kidneys and protect kidney function, it is ideal to drink low-fat foods for a long time to control uric acid below 300 μmol / L. 420 μmol / L is the upper limit of normal blood uric acid. The pathological basis of gout is hyperuricemia. When the uric acid concentration in the blood is higher than normal, it will precipitate in the form of urate crystals and deposit in the joints, cardiovascular system, kidneys, pancreas, etc., usually first manifested as sudden redness, swelling, heat and pain in the joints.

[0017] There are different manifestations at different stages. 1. Asymptomatic hyperuricemia: Blood tests can reveal an increase in blood uric acid concentration, but there are no clinical symptoms such as arthritis, hyperuric acid stones or kidney stones. During this period, it is generally not easy to detect unless a test is done. Asymptomatic hyperuricemia can last for 10 to 20 years, and some people may not develop gout for life. Generally speaking, the higher the blood uric acid level, the greater the risk. 2. Acute hyperuricemia arthritis: It can occur in all seasons, with the most cases in spring and autumn. Local joint injuries, overeating and drinking, excessive fatigue, dampness and coldness, certain drugs, infections and surgical operations can all induce acute attacks.

[0018] According to the mechanism of uric acid production, we can deduce in reverse: to prevent and treat gout, we must reduce the production of uric acid. To reduce the production of uric acid, we must reduce the purine in the body. To reduce the purine in the body, we must reduce the oxidative decomposition of nucleic acids and the intake of purine, and at the same time, we must drink low food to excrete uric acid. A normal human body usually accumulates 1200 mg of uric acid in the body, about 600 mg per day, that is, half of the uric acid in the human body, which is undergoing a new and old alternation. To put it another way, the human body stores about 1200 mg of uric acid, and 600 mg is excreted and 600 mg is newly generated every day. If it is further subdivided, the 600 mg of uric acid newly generated by the human body every day, of which 100 mg is ingested from food, and 500 mg is converted from endogenous purine produced by cell decomposition and decay in the body. As for the 600 mg of uric acid excreted, 450 mg is excreted in urine, and 150 mg is excreted in sweat and feces. Under normal circumstances, the body works in an orderly manner according to this rhythm and law over and over again. However, once this balance is broken, whether the reason is excessive uric acid production or reduced uric acid excretion, uric acid will increase, leading to hyperuricemia and finally gout. Prescription drugs for uric acid excretion: Uric acid excretion drugs mainly include probenecid, sulfinpyrazone, benzbromarone, etc. This type of drug can prevent the reabsorption of uric acid by the renal tubules and increase the excretion of uric acid, thereby playing a role in reducing the level of uric acid in the human body. The side effect is that while excreting more uric acid, other trace elements in the human body are also excreted from the body, which will cause hyponatremia, hypokalemia, and hypocalcemia. Therefore, it cannot be used for a long time, and it also has side effects on the liver and kidneys, let alone long-term use. Drugs that inhibit uric acid production: Allopurinol is currently the most commonly used drug for inhibiting uric acid production in clinical practice. This drug is a powerful purine oxidase inhibitor, and it is also the only drug that can effectively reduce uric acid production and lower uric acid levels in the human body. Although allopurinol has fewer adverse reactions, it should also be used with caution in patients with liver and kidney dysfunction.

[0025] The market prospects for all-in-one dietary supplements suitable for people with six highs are broad.

[0027] In view of this, the present invention provides a nutritional supplement suitable for people with six highs, a tablet thereof and a preparation method thereof. Summary of the invention

[0028] The purpose of the present invention is to provide a nutritional supplement suitable for people with six highs, a tablet thereof and a preparation method thereof.

[0029] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are particularly adopted:

[0030] In a first aspect, the present invention provides a nutritional supplement suitable for people with six highs. The raw materials of the nutritional supplement suitable for people with six highs include chlorella powder, Euglena powder, xylo-oligosaccharides, earthworm protein, natto powder, and tea theanine.

[0031] Furthermore, in a preferred embodiment of the present invention, the raw materials of the nutritional supplement suitable for people with six highs include, by weight, 3500-4000 parts of chlorella powder, 3500-4000 parts of euglena powder, 500-1500 parts of xylo-oligosaccharides, 300-700 parts of earthworm protein, 300-700 parts of natto powder, and 300-700 parts of tea theanine.

[0032] Furthermore, in a preferred embodiment of the present invention, 3600-3900 parts of chlorella powder, 3600-3900 parts of euglena powder, 800-1200 parts of xylo-oligosaccharides, 400-600 parts of earthworm protein, 400-600 parts of natto powder, and 400-600 parts of tea theanine are included.

[0033] Furthermore, in a preferred embodiment of the present invention, 3750 parts of chlorella powder, 3750 parts of euglena powder, 1000 parts of xylo-oligosaccharides, 500 parts of earthworm protein, 500 parts of natto powder, and 500 parts of tea theanine are included.

[0034] In a second aspect, the present invention also provides a method for preparing tablets of a nutritional supplement suitable for people with six highs.

[0035] The raw materials are dried at 38-42°C for 25-35 minutes, taken out and sieved through a 100-mesh sieve, mixed evenly, made into a soft material, sieved through a 12-14 mesh sieve to make wet granules, the granules are dried at 55-65°C for 50-60 minutes, sieved through a 16-18 mesh sieve to size the granules, 0.5% magnesium stearate is added to the granules, mixed evenly, and pressed into tablets.

[0036] Furthermore, in a preferred embodiment of the present invention, the raw material is dried in an oven at 40° C. for 30 min.

[0037] Furthermore, in a preferred embodiment of the present invention, the particles are dried at 60° C. for 55 min.

[0038] Furthermore, in a preferred embodiment of the present invention, the soft material is passed through a 12-mesh sieve to prepare wet granules, and then passed through a 16-mesh sieve to prepare whole granules.

[0039] In a third aspect, the present invention also provides a use of the nutritional supplement or the nutritional supplement tablet in preparing food or health food suitable for people with six highs.

[0040] Compared with the prior art, the beneficial effects of the present invention include:

[0041] Nutritional supplements suitable for people with six highs have significantly improved health indicators compared with existing technologies. DETAILED DESCRIPTION

[0042] The embodiments of the present invention will be described in detail below in conjunction with the examples, but it will be appreciated by those skilled in the art that the following examples are only used to illustrate the present invention and should not be construed as limiting the scope of the present invention. If specific conditions are not specified in the examples, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.

[0043] The features and properties of the present invention are further described in detail below in conjunction with the embodiments:

[0044] Example 1

[0045] Take 3500 grams of protein-core Chlorella powder, 4000 grams of Euglena powder, 1500 grams of xylo-oligosaccharide, 300 grams of earthworm protein, 300 grams of natto powder, and 300 grams of tea theanine.

[0046] The raw materials were dried at 38°C for 35 min, taken out and sieved through a 100-mesh sieve, mixed evenly, made into a soft material, sieved through a 12-mesh sieve to make wet granules, the granules were dried at 65°C for 50 min, sieved through an 18-mesh sieve to size the granules, 0.5% magnesium stearate was added to the granules, mixed evenly, and tablets were obtained.

[0047] Example 2

[0048] Take 4000 grams of Chlorella protein core powder, 3500 grams of Euglena powder, 500 grams of xylo-oligosaccharide, 700 grams of earthworm protein, 700 grams of natto powder, and 700 grams of tea theanine.

[0049] The raw materials were dried at 42°C for 25 min, taken out and sieved through a 100-mesh sieve, mixed evenly, made into a soft material, sieved through a 14-mesh sieve to make wet granules, the granules were dried at 55°C for 60 min, sieved through a 16-mesh sieve to size the granules, 0.5% magnesium stearate was added to the granules, mixed evenly, and pressed into tablets.

[0050] Example 3

[0051] Take 3600 grams of Chlorella protein core powder, 3900 grams of Euglena powder, 1200 grams of xylo-oligosaccharide, 400 grams of earthworm protein, 400 grams of natto powder, and 400 grams of tea theanine.

[0052] The raw materials are dried at 40°C for 25-35 minutes, taken out and sieved through a 100-mesh sieve, mixed evenly, made into a soft material, sieved through a 12-mesh sieve to make wet granules, the granules are dried at 60°C for 55 minutes, sieved through a 16-mesh sieve to size the granules, 0.5% magnesium stearate is added to the granules, mixed evenly, and pressed into tablets.

[0053] Example 4

[0054] Take 3900 grams of Chlorella protein core powder, 3500 grams of Euglena powder, 800 grams of xylo-oligosaccharide, 600 grams of earthworm protein, 600 grams of natto powder, and 600 grams of tea theanine.

[0055] The tablet pressing method is the same as in Example 3.

[0056] Example 5

[0057] Take 3750 grams of Chlorella protein core powder, 3750 grams of Euglena powder, 1000 grams of xylo-oligosaccharide, 500 grams of earthworm protein, 500 grams of natto powder, and 500 grams of tea theanine.

[0058] The tablet pressing method is the same as in Example 3.

[0059] Comparative Example 1

[0060] Take 3750 grams of chlorella powder and add starch to make the total amount of raw materials 10000 grams.

[0061] The tablet pressing method is the same as in Example 3.

[0062] Comparative Example 2

[0063] Take 3750 grams of euglena powder, 1000 grams of xylo-oligosaccharide, 500 grams of earthworm protein, 500 grams of natto powder, and 500 grams of tea theanine, and add starch to make the total amount of raw materials 10000 grams.

[0064] The tablet pressing method is the same as in Example 3.

[0065] Comparative Example 3

[0066] Take 3750 grams of Euglena powder and add starch to make the total amount of raw materials 10000 grams.

[0067] The tablet pressing method is the same as in Example 3.

[0068] Comparative Example 4

[0069] Take 3750 grams of chlorella powder, 1000 grams of xylo-oligosaccharide, 500 grams of earthworm protein, 500 grams of natto powder, and 500 grams of tea theanine, and add starch to make the total amount of raw materials 10000 grams.

[0070] The tablet pressing method is the same as in Example 3.

[0071] Comparative Example 5

[0072] Take 500 grams of natto powder and add starch to make the total amount of raw materials 10,000 grams.

[0073] The tablet pressing method is the same as in Example 3.

[0074] Comparative Example 6

[0075] Take 3750 grams of protein-core Chlorella powder, 3750 grams of Euglena powder, 1000 grams of xylo-oligosaccharide, 500 grams of earthworm protein, and 500 grams of tea theanine, and add starch to make the total amount of raw materials 10000 grams.

[0076] The tablet pressing method is the same as in Example 3.

[0077] Comparative Example 7

[0078] Take 500 grams of theanine from tea leaves and add starch to make the total amount of raw materials 10,000 grams.

[0079] The tablet pressing method is the same as in Example 3.

[0080] Comparative Example 8

[0081] Take 3750 grams of Chlorella powder, 3750 grams of Euglena powder, 1000 grams of xylo-oligosaccharide, 500 grams of earthworm protein, and 500 grams of natto powder, and add starch to make the total amount of raw materials 10000 grams.

[0082] The tablet pressing method is the same as in Example 3.

[0083] Beneficial effects of the present invention:

[0084] 1. Lowering blood lipids and body weight

[0085] (1) Methods

[0086] Male Wistar rats, weighing 180-220g, were randomly divided into a normal control group, a model group, groups 1 to 5 of embodiments, and groups 1 to 8 of comparative examples, with 10 rats in each group. During the experiment, the rats were free to eat ordinary feed and drink water. Every morning, groups 1 to 5 of embodiments and groups 1 to 8 of comparative examples were gavaged with the corresponding samples (samples of embodiments 1 to 5 and comparative examples 1 to 8), and the gavage volume was 0.8g / kg·d, and the other groups were gavaged with the same amount of starch; in the afternoon, the normal control group was gavaged with an equal volume of a mixture of Tween 80 and propylene glycol (volume fraction 1:1), and the other groups were gavaged with a high-fat emulsion (25% lard, 12% cholesterol, 2% sodium cholate, 1% propylthiouracil, 20% Tween 80, 20% propylene glycol, 10% 10% sodium deoxycholate aqueous solution and 10% water), and the gavage dose was 10mL·kg -1 The experimental period was 35 days. After the last administration, the rats were fasted but not watered for 12 hours. After the body weight was measured, the eyeballs were removed to collect blood, which was centrifuged to obtain serum. The total cholesterol (TC), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C) in the serum were measured. See Table 1.

[0087] (2) Blood lipid and body weight test results (see Table 1)

[0088] Table 1

[0089] Group TC(mmol / L) TG (mmol / L) HDL-C (mmol / L) Weight gain (g) Normal control group 1.33±0.27 0.69±0.14 1.17±0.15 2.0±0.6 Model Group 2.51±0.53 1.42±0.29 0.76±0.08 39.7±5.3 Example 1 1.69±0.31 0.91±0.16 1.04±0.11 8.8±1.7 Example 2 1.70±0.31 0.90±0.17 1.02±0.10 8.6±1.6 Example 3 1.62±0.30 0.83±0.15 1.07±0.12 7.9±1.5 Example 4 1.61±0.30 0.84±0.17 1.08±0.10 7.7±1.8 Example 5 1.58±0.27 0.81±0.14 1.10±0.11 6.6±1.5 Comparative Example 1 2.43±0.49 1.39±0.26 0.80±0.10 38.9±4.8 Comparative Example 2 1.85±0.35 0.99±0.20 0.97±0.13 10.7±2.2 Comparative Example 3 2.16±0.44 1.26±0.28 0.91±0.11 25.7±3.2 Comparative Example 4 2.08±0.40 1.18±0.23 0.87±0.12 23.8±3.0 Comparative Example 5 2.13±0.42 1.28±0.29 0.98±0.13 26.3±3.3 Comparative Example 6 2.04±0.38 1.13±0.20 0.93±0.12 21.9±2.8 Comparative Example 7 2.13±0.41 1.20±0.26 0.95±0.13 23.6±3.0 Comparative Example 8 2.06±0.38 1.17±0.21 0.96±0.11 20.8±2.4

[0090] 2. Blood pressure reduction

[0091] (1) Methods

[0092] Spontaneously hypertensive rats were randomly divided into a model group, Example 1-5 groups and Comparative Example 1-8 groups, with 10 rats in each group, half of which were male and half were female. The Example 1-5 groups and Comparative Example 1-8 groups were gavaged with corresponding samples (Example 1-5 and Comparative Example 1-8 samples) at a gavage volume of 0.8 g / kg·d (the model group was gavaged with the same amount of starch) for 5 consecutive weeks, and were kept normally during this period.

[0093] (2) Blood pressure test results (see Table 2)

[0094] After 5 weeks, the spontaneously hypertensive rats were fixed in a 38°C incubator and preheated for 10 min. The blood pressure (systolic pressure) was measured by the tail pulse method.

[0095] Table 2

[0096]

[0097]

[0098] 3. Blood sugar reduction

[0099] (1) Methods

[0100] The mice were randomly divided into a normal control group, a model group, groups 1 to 5 of embodiments and groups 1 to 8 of comparative examples, with 10 mice in each group. Except for the normal control group, which was intervened with physiological saline, the other groups were induced with streptozotocin (STZ) to establish a diabetes model. A sodium citrate-STZ solution with a mass fraction of 4 mg / L was intraperitoneally injected at a dose of 40 mg / kg, once a day, for 5 consecutive days. On the second day, groups 1 to 5 of embodiments and groups 1 to 8 of comparative examples were gavaged with corresponding samples (samples of embodiments 1 to 5 and comparative examples 1 to 8), with a gavage volume of 0.8 g / kg·d (the normal control group and the model group were gavaged with the same amount of starch), for 5 consecutive weeks.

[0101] (2) Blood sugar test results (see Table 3)

[0102] After 5 weeks, the fasting blood glucose of the mice was measured.

[0103] Table 3

[0104]

[0105]

[0106] 4. Uric acid lowering

[0107] (1) Methods

[0108] The mice were randomly divided into a normal control group, a model group, groups 1 to 5 of embodiments and groups 1 to 8 of comparative examples, with 10 mice in each group. Groups 1 to 5 of embodiments and groups 1 to 8 of comparative examples were gavaged with corresponding samples (samples of embodiments 1 to 5 and comparative examples 1 to 8), with a gavage volume of 1.0 g / kg·d (the normal control group and the model group were gavaged with the same amount of starch) for 6 consecutive weeks. Then, except for the blank group, the rest were intraperitoneally injected with 300 mg / kg of potassium oxonate to cause acute hyperuricemia in mice, and 1 hour after the injection of potassium oxonate, the eyeballs of mice in each group were removed and blood was collected in EP tubes. The EP tubes were left to stand in a 37°C water bath until the blood was stratified, and then centrifuged at 1800 r / min for 10 minutes to separate the serum for testing.

[0109] (2) Uric acid test results (see Table 4)

[0110] Uric acid test: Take the serum to be tested and determine the serum uric acid concentration according to the instructions of the kit.

[0111] Table 4

[0112]

[0113]

[0114] In summary, nutritional supplements suitable for people with six highs have significantly improved health indicators compared with the control group.

[0115] The links not described in detail in the present invention are all common knowledge that can be selected by ordinary technicians in the field. Although the present invention has been described in detail above with general descriptions and specific implementation schemes, it is obvious to ordinary technicians in the field that some modifications or improvements can be made on the basis of the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all belong to the scope of protection claimed by the present invention.

Claims

1. A nutritional supplement suitable for people with six highs, characterized in that: The raw materials of the nutritional supplement suitable for people with six highs include protein core chlorella powder, Euglena powder, oligoxylose, earthworm protein, natto powder, and tea theanine.

2. The nutritional supplement suitable for people with six highs according to claim 1, characterized in that: Measured by weight, the raw materials of the nutritional supplement suitable for people with six highs include 3500-4000 parts of the protein core chlorella powder, 3500-4000 parts of euglena powder, 500-1500 parts of xylo-oligosaccharides, 300-700 parts of earthworm protein, 300-700 parts of natto powder, and 300-700 parts of tea theanine.

3. The nutritional supplement suitable for people with six highs according to claim 1, characterized in that: Measured by weight, the raw materials of the nutritional supplement suitable for people with six highs include 3600-3900 parts of the protein core chlorella powder, 3600-3900 parts of Euglena powder, 800-1200 parts of xylo-oligosaccharides, 400-600 parts of earthworm protein, 400-600 parts of natto powder, and 400-600 parts of tea theanine.

4. The nutritional supplement suitable for people with six highs according to claim 1, characterized in that: In terms of weight, the raw materials of the nutritional supplement suitable for people with six highs include 3750 parts of the protein core chlorella powder, 3750 parts of Euglena powder, 1000 parts of xylo-oligosaccharides, 500 parts of earthworm protein, 500 parts of natto powder, and 500 parts of tea theanine.

5. A nutritional supplement according to claim 1, characterized in that: The nutritional supplement is in the form of tablets.

6. A method for preparing tablets of nutritional supplements suitable for people with six highs according to claims 1 to 4, characterized in that: The raw materials are dried at 38-42° C. for 25-35 minutes, taken out and sieved through a 100-mesh sieve, mixed evenly to prepare a soft material, sieved through a 12-14-mesh sieve to prepare wet granules, the granules are dried at 55-65° C. for 50-60 minutes, sieved through a 16-18-mesh sieve to prepare granules, 0.5% magnesium stearate is added to the granules, mixed evenly and pressed into tablets.

7. A method for preparing a tablet of a nutritional supplement suitable for people with six highs according to claim 6, characterized in that: The raw materials were dried in an oven at 40°C for 30 min.

8. A method for preparing a tablet of a nutritional supplement suitable for people with six highs according to claim 6, characterized in that: The granules were dried at 60°C for 55 min.

9. A method for preparing a tablet of a nutritional supplement suitable for people with six highs according to claim 6, characterized in that: The soft material is passed through a 12-mesh sieve to prepare wet granules, and then passed through a 16-mesh sieve to prepare whole granules.

10. Use of the nutritional supplement according to any one of claims 1 to 4 or the nutritional supplement tablet according to any one of claims 5 to 9 in preparing food or health food suitable for people with six highs.

Images